XML 70 R44.htm IDEA: XBRL DOCUMENT v3.22.0.1
Segment, Geographic and Other Revenue Information (Tables)
 12 Months Ended
Dec. 31, 2021
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information by Segment
The following table provides selected income statement information by reportable segment:
 Revenues
Earnings(a)
Depreciation and Amortization(b)
Year Ended December 31,Year Ended December 31,Year Ended December 31,
(MILLIONS OF DOLLARS)20212020 2019 20212020 201920212020 2019
Reportable Segment:
Biopharma$79,557 $40,724 $38,013 $40,226 $27,089 $24,419 $1,439 $1,013 $978 
Other business activities(c)
1,731 926 2,892 (10,396)(12,308)(11,216)598 603 592 
Reconciling Items:
Purchase accounting adjustments— — — (3,175)(3,117)(4,153)3,067 3,047 4,145 
Acquisition-related costs— — — (52)(44)(185)— — 3 
Certain significant items(d)
— — — (2,292)(4,584)2,456 87 18 37 
$81,288 $41,651 $40,905 $24,311 $7,036 $11,321 $5,191 $4,681 $5,755 
(a)Income from continuing operations before provision/(benefit) for taxes on income. Biopharma’s earnings include dividend income from our investment in ViiV of $166 million in 2021, $278 million in 2020 and $220 million in 2019.
(b)Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. Amounts here relate solely to the depreciation and amortization associated with continuing operations.
(c)Other business activities include revenues and costs associated with PC1, as well as costs associated with global WRDM and GPD platform functions, global corporate enabling functions and other corporate items, as noted above, that we do not allocate to our operating segments. In 2019, Other business activities also include revenues and costs associated with our former Consumer Healthcare business through July 31, 2019. See Note 2C.
(d)Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. For Earnings in 2021, includes, among other items: (i) a $2.1 billion charge for IPR&D related to our acquisition of Trillium, which was accounted for as an asset acquisition and recorded in Research and development expenses, (ii) restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring of $1.3 billion ($450 million recorded in Selling, informational and administrative expenses and the remaining amount primarily recorded in Restructuring charges and certain acquisition-related costs) and (iii) upfront and milestone payments on collaborative and licensing arrangements of $1.1 billion recorded in Research and development expenses, partially offset by (iv) actuarial valuation and other pension and postretirement plan gains of $1.6 billion recorded in Other (income)/deductions––net and (v) gains on equity securities of $1.3 billion recorded in Other (income)/deductions––net. For Earnings in 2020, includes, among other items; (i) charges of $1.7 billion related to certain asset impairments recorded in Other (income)/deductions––net, (ii) actuarial valuation and other pension and postretirement plan losses of $1.1 billion recorded in Other (income)/deductions––net and (iii) restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring of $791 million ($197 million recorded in Selling, informational and administrative expenses and the remaining amount primarily recorded in Restructuring charges and certain acquisition-related costs). For Earnings in 2019, includes, among other items: (i) a pre-tax gain of $8.1 billion recorded in (Gain) on completion of Consumer Healthcare JV transaction associated with the completion of the Consumer Healthcare JV transaction, partially offset by (ii) charges of $2.8 billion related to certain asset impairments recorded in Other (income)/deductions––net and (iii) actuarial valuation and other pension and postretirement plan losses of $750 million recorded in Other (income)/deductions––net. For additional information, see Notes 2A, 2C, 3 and 4.
Revenue from External Customers by Geographic Areas
The following summarizes revenues by geographic area:
 Year Ended December 31,
(MILLIONS)202120202019
United States$29,746 $21,455 $20,326 
Developed Europe18,336 7,788 7,729 
Developed Rest of World12,506 4,036 4,022 
Emerging Markets20,701 8,372 8,828 
Revenues
$81,288 $41,651 $40,905 
Schedules of Concentration of Risk
The following summarizes revenue, as a percentage of total revenues, for our three largest U.S. wholesaler customers:
 Year Ended December 31,
202120202019
McKesson, Inc.
9 %16 %15 %
AmerisourceBergen Corporation
7 %14 %11 %
Cardinal Health, Inc.5 %10 %9 %
Schedule of Significant Product Revenues
The following provides detailed revenue information for several of our major products:
(MILLIONS)Year Ended December 31,
PRODUCTPRIMARY INDICATION OR CLASS202120202019
TOTAL REVENUES(a)
$81,288 $41,651 $40,905 
PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA)(a), (b)
$79,557 $40,724 $38,013 
Vaccines$42,625 $6,575 $6,504 
Comirnaty direct sales and alliance revenues
Active immunization to prevent COVID-19
36,781 154 — 
Prevnar family(c)
Pneumococcal disease5,272 5,850 5,847 
Nimenrix
Meningococcal ACWY disease193 221 230 
FSME-IMMUN/TicoVac
Tick-borne encephalitis disease
185 196 220 
TrumenbaMeningococcal B disease118 112 135 
All other Vaccines
Various74 42 73 
Oncology$12,333 $10,867 $9,014 
IbranceHR-positive/HER2-negative metastatic breast cancer5,437 5,392 4,961 
Xtandi alliance revenuesmCRPC, nmCRPC, mCSPC1,185 1,024 838 
Inlyta
Advanced RCC1,002 787 477 
Sutent
Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor
673 819 936 
Bosulif
Philadelphia chromosome–positive chronic myelogenous leukemia540 450 365 
Xalkori
ALK-positive and ROS1-positive advanced NSCLC493 544 530 
Ruxience(d)
Non-hodgkin’s lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis (Wegener’s Granulomatosis) and microscopic polyangiitis491 170 (1)
Retacrit(d)
Anemia444 386 225 
Zirabev(d)
Treatment of mCRC; unresectable, locally advanced, recurrent or metastatic NSCLC; recurrent glioblastoma; metastatic RCC; and persistent, recurrent or metastatic cervical cancer444 143 1 
Lorbrena
ALK-positive metastatic NSCLC
266 204 115 
AromasinPost-menopausal early and advanced breast cancer211 148 136 
Trazimera(d)
HER-positive breast cancer and metastatic stomach cancers
197 98 6 
BesponsaRelapsed or refractory B-cell acute lymphoblastic leukemia 192 182 157 
Braftovi
In combination with Mektovi for metastatic melanoma in patients with a BRAFV600E/K mutation and, in combination with Erbitux® (cetuximab), for the treatment of BRAFV600E-mutant mCRC after prior therapy
187 160 48 
Bavencio alliance revenuesLocally advanced or metastatic urothelial carcinoma; metastatic Merkel cell carcinoma; immunotherapy and tyrosine kinase inhibitor combination for patients with advanced RCC178 80 49 
Mektovi
In combination with Braftovi for metastatic melanoma in patients with a BRAFV600E/K mutation
155 142 49 
All other Oncology
Various238 137 122 
Internal Medicine$9,329 $9,003 $8,790 
Eliquis alliance revenues and direct sales
Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism5,970 4,949 4,220 
Premarin family
Symptoms of menopause563 680 734 
Chantix/Champix
An aid to smoking cessation treatment in adults 18 years of age or older
398 919 1,107 
BMP2
Development of bone and cartilage266 274 287 
Toviaz
Overactive bladder238 252 250 
PristiqDepression187 171 176 
All other Internal Medicine
Various1,706 1,758 2,016 
(MILLIONS)Year Ended December 31,
PRODUCTPRIMARY INDICATION OR CLASS202120202019
Hospital(a)
$7,301 $6,777 $6,695 
Sulperazon
Bacterial infections683 618 684 
MedrolAnti-inflammatory glucocorticoid432 402 469 
ZaviceftaBacterial infections413 212 108 
Fragmin
Treatment/prevention of venous thromboembolism305 252 253 
ZithromaxBacterial infections278 276 336 
Vfend
Fungal infections267 270 346 
TygacilBacterial infections200 160 197 
PrecedexSedation agent in surgery or intensive care177 260 155 
Zyvox
Bacterial infections173 222 251 
Paxlovid
COVID-19 Infection (high risk population)
76 — — 
IVIg Products(e)
Various430 376 275 
All other Anti-infectives
Various1,453 1,294 1,396 
All other HospitalVarious2,412 2,435 2,225 
Inflammation & Immunology (I&I)$4,431 $4,567 $4,733 
Xeljanz
RA, PsA, UC, active polyarticular course juvenile idiopathic arthritis, ankylosing spondylitis2,455 2,437 2,242 
Enbrel (Outside the U.S. and Canada)
RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis
1,185 1,350 1,699 
Inflectra/Remsima(d)
Crohn’s disease, pediatric Crohn’s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis
657 659 625 
All other I&I
Various134 121 167 
Rare Disease
$3,538 $2,936 $2,278 
Vyndaqel/VyndamaxATTR-cardiomyopathy and polyneuropathy2,015 1,288 473 
BeneFIXHemophilia B438 454 488 
Genotropin
Replacement of human growth hormone389 427 498 
Refacto AF/Xyntha
Hemophilia A304 370 426 
Somavert
Acromegaly277 277 264 
All other Rare Disease
Various115 120 129 
PFIZER CENTREONE(b)
$1,731 $926 $810 
CONSUMER HEALTHCARE BUSINESS(f)
$— $— $2,082 
Total Alliance revenues$7,652 $5,418 $4,648 
Total Biosimilars(d)
$2,343 $1,527 $911 
Total Sterile Injectable Pharmaceuticals(g)
$5,746 $5,315 $5,013 
(a)On December 31, 2021, we completed the sale of our Meridian subsidiary. Prior to its sale, Meridian was managed as part of the Hospital therapeutic area. On November 16, 2020, we completed the spin-off and the combination of our Upjohn Business with Mylan to form Viatris. On December 21, 2020, Pfizer and Viatris completed the termination of the Mylan-Japan collaboration. Beginning in the fourth quarter of 2021, the financial results of Meridian are reflected as discontinued operations for all periods presented. Beginning in the fourth quarter of 2020, the financial results of the Upjohn Business and Mylan-Japan collaboration were reflected as discontinued operations for all periods presented. Prior-period financial information has been restated, as appropriate. See Note 1A.
(b)At the beginning of our fiscal fourth quarter of 2021, we reorganized our commercial operations and began to manage our commercial operations through a new global structure consisting of two operating segments, each led by a single manager: Biopharma, our innovative science-based biopharmaceutical business and PC1. PC1, which previously had been managed within the Hospital therapeutic area, includes revenues from our contract manufacturing, including certain Comirnaty-related manufacturing activities performed on behalf of BioNTech ($320 million for 2021 and $0 million for 2020 and 2019), and active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer businesses/partnerships, including but not limited to, transitional manufacturing and supply agreements with Viatris following the spin-off of the Upjohn Business. We have revised prior period information to conform to the current management structure.
(c)Prevnar family include revenues from Prevnar 13/Prevenar 13 (pediatric and adult) and Prevnar 20 (adult).
(d)Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima, Ruxience, Retacrit, Zirabev and Trazimera.
(e)Intravenous immunoglobulin (IVIg) products include the revenues from Panzyga, Octagam and Cutaquig.
(f)On July 31, 2019, our Consumer Healthcare business, an OTC medicines business, was combined with GSK’s consumer healthcare business to form a new consumer healthcare JV. See Note 2C.
(g)Total Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital therapeutic area, including anti-infective sterile injectable pharmaceuticals.